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Abstract:
Developing new medicines is a complex process where understanding the reasons for both failure and success take us forwards. One gap in our understanding of most candidate stroke drugs before clinical trial, is whether they have a protective effect on human tissues. NXY-059 is a spin-trap reagent hypothesized to have activity against the damaging oxidative biology which accompanies ischemic stroke. Re-examination of the preclinical in vivo data set for this agent in the wake of the failed SAINT-II RCT highlighted the presence of a range of biases leading to overestimation of the magnitude of NXY-059’s effects in laboratory animals. Therefore NXY-059 seemed an ideal candidate to test in human neural tissues. 
The aim of this randomized and blinded study was to assess the effects of NXY-059 on human stem cell derived neurons in the presence of ischaemia-like injury induced by oxygen glucose deprivation or oxidative stress induced by hydrogen peroxide or sodium nitroprusside. In MTT assays of cell survival, LDH assays of total cell death and Tunel staining of apoptotic-like cell death, NXY-059 at concentrations ranging from 1µM to 1mM was completely without activity. Conversely an antioxidant cocktail comprising 100µM each of ascorbate, reduced glutathione and dithiothreitol used as a positive control provided marked neuronal protection in all these assays.


Introduction:
Stroke is the second most common cause of death and disability. Approximately 15 million people have a stroke each year, 6 million die and ~30% of the 55 million survivors have significant neurological impairment []. The cost of stroke is high with some estimates suggesting stroke costs the developed world up to US$1038 billion each year []. Despite intensive research effort we have only one effective approved drug for acute ischemic stroke, tissue plasminogen activator (tPA) which is used for thrombolysis to restore blood flow in the first 4.5 hours after stroke. Although tPA was licensed by the FDA in 1996 it is still only used in 2-5% of patients because a narrow time window and risk of bleeding limit its use[]. Moreover, despite thrombolysis, around half of the treated patients remain dependent or die  ADDIN EN.CITE []. Recent positive results for trials of tenecteplase  ADDIN EN.CITE [] and thrombectomy  ADDIN EN.CITE [] offer some hope for the future but there remains substantial unmet need in the treatment of acute stroke. There is an urgent requirement for therapies able to treat the wider population.
Disodium 2, 4-sulphophenyl-N-tert-butylnitrone (NXY-059) is a free radical spin trap agent reported to reduce infarct volume in both rodent and primate models of stroke  ADDIN EN.CITE []. The translational promise offered by these publications and unpublished in-house data held by AstraZeneca, together with evidence of safety in control  ADDIN EN.CITE [, ] and acute stroke populations  ADDIN EN.CITE [] led AstraZeneca to conduct two Phase III randomized placebo-controlled trials of the use of NXY-059 within 6 hours of stroke onset  ADDIN EN.CITE [, ]. Whilst the first of these provided a weak positive signal in primary and secondary analyses  ADDIN EN.CITE [] the second and larger trial (3306 vs 1722 patients) was neutral, providing no evidence for efficacy of NXY-059 in stroke patients  ADDIN EN.CITE []. Pooled analysis of both data sets also failed to detect any effect on stroke outcomes including rates of symptomatic or asymptomatic hemorrhage among patients treated with Alteplase  ADDIN EN.CITE [].
Numerous commentaries offered hypotheses to explain these results. These ranged from criticism of the statistical methods used to detect the first positive clinical outcome and of the selection of NXY-059 over other apparently more effective spin-trap agents [], through pleas for better concordance between animal and human experiments  ADDIN EN.CITE []. Suggestions were even made that AstraZeneca might have inadvertently supplied the SAINT-II trialists with an inactive drug preparation []. 
Critical re-analysis of the preclinical data sets used to support the decision to proceed to clinical trial offered a less palatable explanation. The empirical evidence suggests that bias in the conduct of animal studies led to an inflated estimate of efficacy. Two independently performed and methodologically distinct systematic reviews and meta-analyses both raised concerns about the impact of randomization and blinding on detected outcome and also pointed out that little activity was detected in hypertensive animals  ADDIN EN.CITE [, ] suggesting that translation to an often hypertensive patient population might prove difficult. The individual animal meta-analysis  ADDIN EN.CITE [] also found an unexpectedly high proportion of treated animals with no lesion compared to controls (7% vs 0%; P = 0.001). Whilst it is possible that this signified complete success, the more parsimonious explanation is that animals with failed stroke procedures were accepted into the treated cohorts.
The published in vitro data, which did not pre-date the in vivo data, were also equivocal. One study using rat cortical brain slices concluded that NXY-059 improved neuronal survival  ADDIN EN.CITE []. However another study in mouse neuroblastoma cells reported no effect []. Another study reported that NXY-059 restored endothelial blood brain barrier function as measured by sucrose transport  ADDIN EN.CITE [] yet an earlier study also in an endothelial culture model of blood brain barrier function, reported negligible [14C] NXY-059 uptake under any experimental conditions and reported no protective effect on cellular metabolism as assessed by measurement of ATP concentration  ADDIN EN.CITE []. 
Until recently it has not been practical to screen candidate stroke drugs for relevant activities in human neural tissues. Advances in stem cell biology mean this is no longer true. We have developed a system in which injuries relevant to stroke biology can be imposed on human stem cell-derived neurons in order to allow proof of principle screening of drugs for human activity [] . In light of this uncertainty and to help understand further why the clinical development of NXY-059 might have failed we felt it was important to determine whether NXY-059 provided any protection to these human neurons. 


Materials and methods:
These experiments were conducted in accordance with the guidelines and regulations of the NHMRC and with the approval of the Austin Health Human Research Ethics Committee (Approval number H2008/03194), and University of Melbourne Human Research Ethics Committee (Approval number 0605017).

Materials:
“Disodium 2,4-sulphophenyl-N-tert-butylnitrone was obtained from Tocris (Bristol UK, 3645). The stock solutions for both NXY-059 and the antioxidant cocktail (100µM each of ascorbate, reduced glutathione and dithiothreitol) were prepared in phosphate buffered saline (PBS) on the day of use in reduced light and the stock and working solutions were kept in an aluminium foil wrapped bottle. Electro Spray mass spectrometry in positive ionisation mode identified ions with mass/charge ratios of 404 (NXY-059+Na) and 785 (2NXY-059+Na) consistent with the published mass of 381 Da (m/z Na =23). The proton MR spectrum was also consistent with NXY-059, showing the same proton environments as the data sheet supplied by Tocris. All other media and media supplements were sourced from Invitrogen unless otherwise stated.

Neuronal differentiation:
All methods in this study have been described previously []. In brief H9 (WA-09, WiCell) human embryonic stem cells (hESC), were cultured on Mitomycin-C treated human foreskin fibroblasts (HFF) at 37°C in 5% CO2. Colonies were mechanically dissected every 7 days and transferred to freshly prepared HFFs. Media was changed every second day. Neuronal differentiation was achieved using the Noggin induction method []. The colonies were maintained (37oC, 5% CO2) in presence of 500ng/ml of Noggin for 14 days with the media and Noggin replaced every second day. At this point the colonies were again mechanically dissociated, and transferred to individual wells in a low adherent 96-well plate containing Neural Basal Media (NBM) comprising Neurobasal A (Invitrogen, 10888-022) supplemented with 2% B27 (Invitrogen, 17504-044), 1% Insulin, Transferrin, Selenium-A (Invitrogen, 51500-056), 1% N2 (Invitrogen, 17502-048), 2mM Glutamine, 0.5% Penicillin-streptomycin solution (Invitrogen, 15070-063), 20ng/ml human recombinant EGF (Invitrogen, PHG0314) and 20ng/ml human recombinant bFGF (Invitrogen, 13256-029). Media was changed every 2 to 3 days to allow neurosphere formation over 2 weeks. In order to facilitate neuronal differentiation, neurospheres were again separated into smaller pieces under a dissection microscope with three to four pieces transferred to each well of a 96-well plate (pre-coated with poly-D-lysine (Sigma, P6407, 10µg/ml) and mouse laminin (Invitrogen, 23017015,10µg/ml). The cells were then grown for 11 days (with media changed every two days) in NBM lacking growth factors prior to induction of injury and assessment of NXY-059.

Injury induction
On the day of experimentation, the medium was changed to NBM+N2 containing a B27 preparation lacking the usual antioxidants (Invitrogen, 10889-038) (NBM-AO) to eliminate their confounding effects. Two different injury models, oxygen glucose deprivation and oxidative stress, were used to assess the effect of NXY-059 in these cells. 

Oxygen-Glucose Deprivation 
For combined oxygen and glucose deprivation (ODG), 25mM 2-deoxy-D-glucose was added to NBM-AO medium and equilibrated for 30 minutes at room temperature before placing the cells into a hypoxic chamber flushed with nitrogen for 20 min and maintained at 37oC for 4 hours. Different concentrations of NXY-059 (1µM – 1mM) were added at the time of injury. Following the four hour incubation the medium was collected and analyzed for lactate dehydrogenase activity (LDH) as a marker of cell death. 

Oxidative stress
Oxidative stress injury was induced by using two different methods. In the first experiment, oxidative stress was induced by adding 50µM of fresh H2O2 (Sigma, H1009) to the NBM-AO for 4 hours (37oC, 5% CO2). Different concentrations of NXY-059 (1µM – 1mM) or an antioxidant (AO) cocktail containing 100µM each of ascorbate, reduced glutathione and dithiothreitol were added at the time of injury. The purpose of the antioxidant cocktail was to serve as a positive control in the assay systems used in the study. 
Following the four hour incubation the medium was collected and analyzed for LDH activity.
In the second experiment, 300µM of NXY-059 or the antioxidant (AO) cocktail were administered to the cells 30 minutes prior to the induction of injury. Oxidative stress was then induced either by the administration of either 50µM or 90µM H2O2, or administration 100µM of sodium nitroprusside (SNP, another compound involved in the formation of free radicals) 30 minutes after drug administration. Cultures were maintained under these conditions for 24h before assaying for cell viability using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay of NAD(P)H-dependent cellular oxidoreductase activity and Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) as a method for detecting DNA fragmentation.

Time point experiments:
To evaluate the effects of NXY-059 over time from the induction of injury, 300µM of NXY-059 was applied immediately, or 1, or 3, or 6 hours after induction of injury and maintained for a total of 24 hours in each of the models. 

Cell death/ survival analysis:
LDH, a marker of total cell death and TUNEL staining, a marker of DNA damage typical of apoptosis, were performed according to the kit manufacturer’s instructions (Roche, 1164479001 and 11684795910 respectively). For LDH assays, three control measurements were made in addition to the test sample measurements. The cell culture medium without cells was assayed to assess background activity. Uninjured cells were assayed to detect activity due to basal cell death, and maximum possible cell death (100%) was detected by measuring LDH activity of cells lysed by 1% Triton X-100 solution. 
Cell survival following SNP and H2O2 treatment was assessed using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. MTT is a water soluble compound that interacts with active mitochondrial complex II to form a purple formazan pigment, the absorbance of which can be measured at 570nm. A decrease in MTT formazan density indicates a decrease in mitochondrial activity, which is a marker of reduced cell survival.

Immunohistochemistry:
As reported previously [] hESC culture and differentiation reproducibly yielded cultures enriched for cells with neuron-like morphology and bearing neuronal antigens detected by immunohistochemistry.  β-III tubulin positive cells comprised 70·4% ± 1·8 of the cells present before injury (obtained by calculating the ratio of 4’,6-diamidino-2-phenylindole dihydrochloride (DAPI) and β-III tubulin cells from 10 fields per well in three independent experiments). ~60% of cells expressed MAP-2 and cells expressing the astrocytic marker GFAP comprised <30% of the detected cells. By this stage in culture, no cells remained positive for the stem-cell/progenitor marker OCT-4. 

Statistical Analysis:
Each experiment was repeated three times. To avoid systematic errors within individual cultures because of the arrangement of wells in the tissue culture plates, control and test cultures were randomized across the plates using a block design assigning different preparations to different columns of wells. To minimize any systematic bias in counting of TUNEL positive cells, images of the wells were captured and re-coded before quantitation by an individual blind to experimental allocation. No additional blinding was performed for the machine-read LDH assay process. Within experiments, each comparison was performed in triplicate and the mean of these values taken forward into group comparisons. Two-way ANOVA was performed, followed by post-hoc Dunnett's multiple comparison test with significance set at p<0.05 using SPSS (Statistics 20). All values are presented as mean ± SEM.
 


Results
We carried out extensive methodological work-up to ensure that the assay systems and injury models used had the sensitivity to detect an influence of NXY-059 on neuron survival if it existed. 
50µM H2O2 or OGD of 25mM 2-deoxy-D-glucose combined with oxygen deprivation for 4 hours at 370C reproducibly induced 30–40% reduction of maximal signal detectable by LDH assay (Figure 1A&B). Both hypoxia and glucose deprivation were required for full expression of injury in the OGD model (Figure 1A).
After H2O2 induced oxidative stress, the AO cocktail provided protection, reducing cell death by 72% (p≤0.0001; 95%CI 37.8-105.3) but no NXY-059 concentration had an effect (Figure 2A). 
Following OGD injury, the antioxidant cocktail containing 100µM of ascorbate, again reduced glutathione and dithiothreitol reduced LDH detected cell death by 55% after correcting for basal injury in controls (p≤0.00001; 95% CI 83.6-27.8). In contrast, NXY-059 at concentrations ranging from 1µM to 1mM had no discernable effect on cell death (Figure 2B).
To determine whether timing of NXY-059 dosing might matter, we repeated the experiments using 300µM of NXY-059 (chosen to approximate the 260µM concentration used in the SAINT II clinical trial) delivered at either onset of injury or 1, 3 or 6 hours later to encompass the range of time to treatment encountered in the SAINT clinical trials  ADDIN EN.CITE [, ]. No protective or indeed deleterious effect of NXY-059 was revealed by this strategy for either H2O2 or OGD induced injury (Figure 3A&B). 
To ensure that our inability to detect an effect of NXY-059 was not just due to our choice of assay system, we employed an additional model using sodium nitroprusside (SNP) to induce oxidative stress[] . In this system, we measured cell viability by the MTT assay 24 hours after the start of the experiment. In control uninjured cultures neither NXY-059 nor the AO cocktail influenced neuronal viability. SNP injury itself caused a 44% reduction of cell survival. The AO cocktail increased cell survival by 25% compared to the SNP injury control condition. Administration of 300µM of NXY-059 had no effect (Figure 4A).  
We repeated subcomponents of our earlier H2O2 induced injury experiments to confirm that the MTT assay of cell viability returned a comparable result to the LDH assay of cell death. Two concentrations of H2O2 (50 and 90µM) were used. The AO cocktail significantly improved cell viability by 27% and 31% at 50 µM and 90µM of H2O2 respectively (Figure 4A). NXY-059 was without effect. 
We used TUNEL staining to determine the proportion of cells in each of the above cultures exhibiting DNA damage associated with an apoptotic mechanism of cell death (Figure 4B). Under control conditions fewer than 10% of cells were TUNEL+. 100µM SNP, 50µM H2O2 and 90µM H2O2 increased TUNEL staining by 10%, 15% and 31% respectively.  The AO cocktail reduced this apoptotic death by 7.4%, 8.8% and 14% respectively. NXY-059 was again without effect (Figure 4B).

Discussion
Although large numbers of novel neuroprotective treatment strategies are developed in laboratories each year and are reported to show beneficial effects in animal models of stroke, when assessed in 2006 none had succeeded when subject to the rigors of clinical trial []. Failure of the SAINT-II clinical trial of the free radical spin trap agent disodium 2, 4-sulphophenyl-N-tert-butylnitrone (NXY-059) as a neuroprotectant for stroke marked a turning point in stroke and indeed neuroscience research as a whole  ADDIN EN.CITE []. More recent and also well designed and conducted trials such as the FAST-MAG trial of early magnesium to target the excitotoxic cascade have also joined the list of translational failures [] where  better preclinical data might have suggested greater caution  ADDIN EN.CITE []. This history of translational failures in stroke and other areas of neuroscience have undoubtedly contributed to substantially reduced neuroscience investment by many major players in the pharmaceutical industry [, ]. 
Understanding the reasons for past failures is a cornerstone of scientific progress and essential for the ability to garner support for future experimentation including clinical trials. We and others have already reported that the choice of experimental model and the presence of bias may have led to an overly optimistic use of pre-clinical data encouraging the clinical trials of NXY-059  ADDIN EN.CITE [, ]. Moreover, the published in vitro data was also equivocal  ADDIN EN.CITE []. In this study we sought to take advantage of new stem cell technologies to determine whether NXY-059 was in fact able to protect human neurons derived from hESC’s against model injuries likely to be encountered by neurons during human stroke.
In the first part of this study, cell death detected by LDH assay was measured when two injury models were used, oxygen glucose deprivation (OGD) and oxidative stress induced by H2O2. We have previously shown that this model system is able to detect a marked beneficial effect of hypothermia []  and in these studies we were able to show that a commonly used anti-oxidant cocktail of ascorbate, reduced glutathione and dithiothreitol [] also provided significant neuroprotection, confirming that the assay systems were functioning. However, NXY-059 at concentrations ranging from 1µM to 1mM was without effect (Figure 2). Measuring cell viability by MTT assay and counting apoptotic cells detected by TUNEL staining over a more sustained period in culture (24 hrs rather than 4 hrs) returned the same result (Figures 4).  
Using SNP induced oxidative stress provided an additional model of injury but did not change the result, while the AO cocktail provided protection, NXY-059 was without effect (Figure 4).
This data confirms a previously published study using mouse neurons derived from the murine neuroblastoma N1E-115 cell line in which NXY-059 had no beneficial effect on neuronal survival []. While another study using OGD in a postnatal day-7 rat brain slice model reported that NXY-059 provided a modest degree of protection compared with the cardiac glycoside neriifolin  ADDIN EN.CITE [] at concentrations ranging from 1-100µM. This is not the case in our hands where no protection was seen at concentrations ranging from 1µM to 1mM in human neurons (Figure 2). These observations do not support the hypothesis that NXY-059 has the ability to protect human neurons.
Detection of poor blood brain barrier permeability of NXY-059 in vivo led the authors of one paper to hypothesize that if it didn’t reach neurons perhaps the reported protective properties of NXY-059 might occur because of endothelial rather than neuronal protection  ADDIN EN.CITE []. Certainly, follow on studies reported that NXY-059 reduced the increase in sucrose transport normally associated with OGD in bovine brain capillary endothelial cells co-cultured with rat glial cells  ADDIN EN.CITE []. However, an earlier paper using the same OGD and culture methods had found negligible uptake of NXY-059 into bovine cerebral endothelial cells, no protection of the energy metabolism of the cells and no change in their vesicular transport or integrity of their barrier properties  ADDIN EN.CITE []. The interpretation of these observations remains equivocal at best. 

Conclusions
Developing a new model system to assess the relative merits of candidate drugs for selection for clinical trial always presents one unavoidable conundrum, that until agents have been subject to both testing in the new model and in clinical trial, the predictive value of the model remains uncertain. This conundrum led us to evaluate NXY-059. 
In this study, using human neurons subject to a range of injuries, we have shown that NXY-059 has no effect on human neuronal survival. This is consistent with post-hoc meta-analyses of the experimental animal in vivo data which indicate that the reported effects of NXY-059 were inflated by bias and had limited examination of the likelihood of generalizability. It is also consistent with equivocal in vitro and in vivo evidence for an effect on survival of the blood brain barrier which might have secondarily influenced neuronal survival. Taken together, the evidence suggests that failure rather than success might have been predicted for clinical trials of this agent.  
All studies and their interpretation have limits. While the cells used in these experiments exhibited a mature structural and antigenic phenotype, we have not yet been able to explicitly test NXY-059 in cells exhibiting the entire range of neurochemical encoding possible in the brain. Beneficial effects might be restricted to specific neurochemical profiles present at high abundance in areas of the brain affected in human stroke but not present in our cultures. For example, we have not examined the effects of NXY-059 in the face of excitotoxic injury because none of the neurons in our cultures exhibit significant NMDA receptor expression. Experimentation in human brain slices might theoretically provide a more informative and relevant model system, however this human tissue is not readily available and is unlikely to ever permit high throughput screening of novel candidates. Similarly, more complex mixed human culture systems of neurons, astrocyres, pericytes and endothelial cells that might recapitulate key facets of blood brain barrier behavior are underdevelopment but not available to us. Also we have not been able to test the hypothesis that protection might have been conferred by an undescribed metabolite of NXY-059. 
Nevertheless, the evidence presented here suggests that a human in vitro system to test prospective therapeutic agents for treatment of stroke, and indeed other diseases, has the potential to provide a useful precursor to whole animal studies on the path to human clinical trials.



Legend to Figures:
Figure 1. Dose response relationships for the degree of LDH detected cell death caused by A) Oxygen Glucose Deprivation and B) H2O2 induced oxidative stress. Grey shaded columns indicate concentrations chosen for routine assay.
Figure 2.  NXY-059 had no neuroprotective effect at any of the doses tested on LDH release assay of cell death following 4 hours of: A) H2O2 or B) OGD in embryonic stem cell-derived human neurons. Dotted line = baseline correction value, AO = antioxidant cocktail. # p≤0.0001, ##p≤0.00001.
Figure 3. Varying the timing of delivery 300µM NXY-059 from 0-6 hours after induction of either A) H2O2 or B) OGD injury does not affect LDH detected cell death in embryonic stem cell-derived human neurons. Dotted line = baseline correction value.
Figure 4: Pretreatment with 300µM NXY-059 had no protective effect in human embryonic stem cell-derived neurons following oxidative stress injury induced by SNP and H2O2 when assessed by A) MTT and B) TUNEL staining. AO = antioxidant cocktail. ** p≤0.001, *p≤0.05.
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